177Lu-FAP-2286 Treatment in Urethelial Neoplasms: Utility and Safety as a Novel Treatment.

Description:

Ga-68-FAPI has recently been proven to be superior to F-18-FDG in various cancers. These results have also raised hope in using FAP radiopharmaceuticals with theranostic approach. Lu-177 bound FAPI molecules have been started to be used in some cancers in clinical trials following its efficacy proven by case reports. Similarly,as a pilot study, this project aims to investigate safety and efficacy of Lu-177- FAP-2286 in metastatic urothelial carcinomas of bladder.

Sponsor:

Ankara University

Contacts:

Cigdem Soydal (Professor)

csoydal@yahoo.com

+903125956732

Isotope(s):
Target(s):
  • FAP
XCancer

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468